Xenon Pharmaceuticals Introduces New Equity Inducement Grants
VANCOUVER, British Columbia and BOSTON — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company with a strong emphasis on neuroscience, has taken a significant step to nurture its workforce. The company recently announced equity inducement grants for four new non-officer employees, which consists of a total of 78,600 share options along with 1,800 performance share units (PSUs). These grants were approved by the Compensation Committee of the Company’s Board of Directors and are structured to help attract talented individuals to join their mission.
Details of the Inducement Grants
The share options provided to the new employees come with an exercise price of $38.28 per common share, aligning perfectly with the closing price per share of Xenon’s common stock on the day of the grant. The share options will gradually vest over a four-year period, starting with 25% vesting on the one-year anniversary of each employee’s start date. After this point, the remaining options will vest monthly at a rate of 1/36th on the last day of each month, provided the recipients continue to serve the company.
In addition to share options, the performance share units will vest based on achieving specific milestone-based objectives, which will unfold over a three-year timeline. This aligns with Xenon’s commitment to performance and results-driven growth.
A Commitment to Life-Changing Therapeutics
Founded with a mission centered around neuroscience, Xenon Pharmaceuticals (Nasdaq: XENE) is committed to creating therapeutic solutions that have the potential to significantly change patients' lives. The company specializes in an innovative ion channel product portfolio aimed at addressing areas of high unmet medical need. This includes critical conditions such as epilepsy and depression, where improved treatment options can drastically affect patient outcomes.
Among their most notable developments is Azetukalner, touted as a groundbreaking KV7 potassium channel opener. This compound stands out as the most advanced potassium channel modulator currently in late-stage clinical development, marking a significant breakthrough for multiple indications. Xenon’s concerted efforts in research and development underlines their dedication to bringing new hope to patients.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals stands at the forefront of biopharmaceutical innovations. Through an unwavering focus on neuroscience, they are advancing research that leads to effective treatments and potentially transformative therapies. The company’s team of experts works diligently to navigate the complexities of drug development, ensuring their solutions not only target the underlying conditions but also improve the quality of life for many individuals worldwide.
For those interested in learning more about their exciting pipeline and ongoing initiatives, visiting their official website provides an in-depth look at their projects and research areas.
Company Contacts
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
Frequently Asked Questions
What are equity inducement grants?
Equity inducement grants are stock options or units offered to new employees as a part of their compensation package to incentivize them in their new roles.
Why is Xenon Pharmaceuticals offering these inducement grants?
The grants are a strategic move to attract talented employees who can contribute to the company's mission of developing life-changing therapeutics.
Who approved the inducement grants at Xenon Pharmaceuticals?
The Compensation Committee of the Company’s Board of Directors approved the equity inducement grants.
What is the significance of the exercise price for the options?
The exercise price of $38.28 matches the closing price of Xenon’s stock on the grant date, ensuring that the employees can benefit from the company's growth.
What conditions must be met for the PSUs to vest?
The PSUs will vest based on the achievement of specific predefined milestone-based objectives over a performance period of approximately three years.
